Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin.
The administration of a single intravenous injection of indomethacin was followed by a major constrictive effect on the ductus in 36 of 42 very-low-birth-weight (less than or equal to 1000 gm) infants with symptomatic patent ductus arteriosus (PDA). In 26 of the 36 responders, the effect was sustained; symptomatic PDA recurred in the remaining 10. Infants who experienced a recurrence of symptomatic PDA had lower birth weights and had received indomethacin at an earlier postnatal age than did infants with a sustained effect. These results may be explained by differences in the production and clearance of prostaglandins or in the sensitivity of the ductus to prostaglandin effects between infants with a recurrence and infants with sustained constriction of PDA.
D004374:Ductus Arteriosus, Patent / Q000188:drug therapy* / Q000401:mortality; D004452:Echocardiography; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects* / Q000627:therapeutic use; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000401:mortality; D007275:Injections, Intravenous; D008297:Male; D010366:Peak Expiratory Flow Rate; D011453:Prostaglandins / Q000494:pharmacology; D012008:Recurrence
D011453:Prostaglandins; D007213:Indomethacin